Table 1.
Baseline characteristics of six included trials
| Authors/years | Population | Induction therapy | Treatment group | Maintenance regimen | No. of patients | Median age | Median PFS | Median OS | Jadad score |
|---|---|---|---|---|---|---|---|---|---|
| Barlesi F. et al./2013 | CT-naïve, Stage IIIB–IV, non-squamous, ECOG PS 0–2 | Pemetrexed +cisplatin +bevacizumab | Experimental arm (doublet) | Bevacizumab +pemetrexed | 128 | NR | 7.4 (0.48, 0.35–0.66 | 19.8 (0.88, 0.63–1.21) | 3 |
| Control arm (single agent) | Bevacizumab | 125 | NR | 3.7 | 15.9 | ||||
| Johnson B.E. et al./2013 | CT-naïve, Stage IIIB–IV, or recurrent, ECOG PS 0–1 | Chemotherapy +bevacizumab | Experimental arm (doublet) | Bevacizumab erlotinib | 370 | 64 | 4.8 (0.71, 0.58–0.86 | 14.4 (0.92, 0.70–1.21) | 5 |
| Control arm (single agent) | Bevacizumab placebo | 373 | 64 | 3.7 | 13.3 | ||||
| Patel J.D. et al./2013 | CT-naïve, non-squamous, Stage IIIB–IV, or recurrent, ECOG PS 0–1 | Chemotherapy +bevacizumab | Experimental arm (doublet) | Bevacizumab +pemetrexed | 292 | 63.8 | 6 (0.73, 0.71–0.96 | 12.6 (1, 0.86–1.16) | 3 |
| Control arm (single agent) | Bevacizumab | 298 | 64.3 | 5.6 | 13.4 | ||||
| Karayama M. et al./2016 | CT-naïve, non-squamous, Stage IIIB–IV, or recurrent, ECOG PS 0–1 | Pemetrexed +carboplatin +bevacizumab | Experimental arm (doublet) | Bevacizumab +pemetrexed | 45 | 66 | 11.5 (0.73, 0.44–1.19 | 24.4, 0.87, 95% CI: 0.49e1.54 | 3 |
| Control arm (single agent) | Pemetrexed | 35 | 65 | 7.3 | 21.3 | ||||
| Ciuleanu T.E. et al./2017 | CT-naïve, Stage IV, or recurrent, ECOG PS 0–1 | Platinum-based chemotherapy | Experimental arm (doublet) | Linsitinib +erlotinib | 102 | 62 | 125, 1.09 (0.788–1.507) | 381, 1.20 (0.777, 1.853) | 5 |
| Control arm (single agent) | Placebo +erlotinib | 103 | 60 | 129 | 421 | ||||
| Niho S. et al./2017 | CT-naïve, Stage IIIB–IV, or recurrent, ECOG PS 0–1 | Platinum-based chemotherapy | Experimental arm (doublet) | S-1+bevacizumab | 39 | 61 | 4.6 (0.64, 0.45–0.91 | 19.9 (0.65, 0.41–1.02) | 3 |
| Control arm (single agent) | Bevacizumab | 40 | 65 | 2.6 | 11.0 |
Abbreviations: CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; NR, not reported; OS, overall survival; PFS, progression-free survival; PS, performance status.